Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, April 30, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, purchased 6000 American Depositary Shares (ADSs) at a total price of USD5.887 per ADS.
In addition, Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 2025 American Depositary Shares (ADSs) at a price of USD6.04 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Denise Scots-Knight |
2 |
Reason for the notification |
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
USD5.87 USD5.90 |
3000 3000 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 6000 Aggregated price: USD5.887 |
e) |
Date of the transaction |
2019-04-29 |
f) |
Place of the transaction |
XNMS |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Richard Jones |
2 |
Reason for the notification |
a) |
Position/status |
Chief Financial Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
ADS |
b) |
Nature of the transaction |
Purchase |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
USD6.04 |
2025 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 2025 Aggregated price: USD6.04 |
e) |
Date of the transaction |
2019-04-29 |
f) |
Place of the transaction |
XNMS |